Skip to main navigation

Immunocore

Primary Menu

Overview
News & Events
Stock Information
- Stock Quote & Chart
- Analysts Coverage
Corporate Governance
Financials & Filings
- SEC Filings
IR Resources

Primary Menu

Overview
News & Events
Stock Information
- Stock Quote & Chart
- Analysts Coverage
Corporate Governance
Financials & Filings
- SEC Filings
IR Resources

News Releases

Breadcrumb

Home /
Investor Relations /
News & Events /
News Releases

Year

20 September 2021

Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial

13 September 2021

Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021

10 September 2021

Immunocore to present at upcoming investor conferences

8 September 2021

Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

24 August 2021

Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

11 August 2021

Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update

4 June 2021

Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

27 May 2021

Immunocore to present at upcoming investor conferences

18 May 2021

Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B

12 May 2021

Immunocore Reports First Quarter 2021 Financial Results

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 1 - 10 of 121

Site - Shareholder Tools

Immunocore

Site - Footer Social

About us
Our science
Our therapy areas
For patients

News
Careers
Contact us

Privacy and Social Media Guidelines
Cookies
Payments and Disclosures
Clinical trials

©2021 Immunocore, Ltd. All rights reserved. ImmTAC, ImmTAV, ImmTAB, ImmTAAI and ImmTAX are all registered trademarks of Immunocore, Ltd